Management of joint replacement surgery with a von Willebrand factor product with a low FVIII content in von Willebrand disease patients

被引：0
|
作者：
Borel-Derlon, A. [1 ]
Federici, A. B. [2 ]
Goudemand, J. [3 ]
Roussel-Robert, V [4 ]
Chatelanaz, C. [6 ]
Henriet, C. [6 ]
Bridey, F. [6 ]
机构：
[1] Univ Hosp, Haemophilia Treatment Ctr, Caen, France
[2] Univ Milan, Bianchi Bonomi Haemophilia & Thrombosis Ctr, I-20122 Milan, Italy
[3] Univ Hosp Lille, Haemophilia Treatment Ctr, Lille, France
[4] Univ Hosp Paris Cochin, Haemophilia Treatment Ctr, Paris, France
[5] Haemophilia Treatment Ctr, Montpellier, France
[6] LFB, Les Ulis, France
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2011年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-WE-469
引用
收藏
页码：668 / 668
页数：1
相关论文
共 50 条
  • [1] Management of dental extractions by a von Willebrand factor product VWF with low FVIII content (Wilfactin®) in von Willebrand disease patients
    Borel-Derlon, A.
    Federici, A.
    Chatelanaz, C.
    Bridey, F.
    HAEMOPHILIA, 2008, 14 : 36 - 36
  • [2] Efficacy and safety of a von Willebrand factor concentrate with a low FVIII content in children with von Willebrand disease (vwd)
    Borel-Derlon, A.
    Aronis, S.
    Platokouki, H.
    Maes, P.
    Chatelanaz, C.
    Bridey, F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 530 - 530
  • [3] von Willebrand disease and von Willebrand factor
    Sadler, Brooke
    Castaman, Giancarlo
    O'Donnell, James S.
    HAEMOPHILIA, 2022, 28 : 11 - 17
  • [4] von Willebrand Factor and von Willebrand Disease
    王兆钺
    血栓与止血学, 2005, (04) : 147 - 149
  • [5] FVIII ''synthesis'' and decay in patients with von Willebrand's disease after von Willebrand factor (human) infusion
    Ounnoughene, N
    Stieltjes, N
    FontenayRoupie, M
    Vassilieff, D
    Sultan, Y
    THROMBOSIS AND HAEMOSTASIS, 1997, : P2103 - P2103
  • [6] von Willebrand disease patients with associated risk factor(s) of venous thromboembolism: efficacy and safety of a von Willebrand factor product with a low factor VIII content
    Goudemand, J.
    Borel-Derlon, A.
    Federici, A. B.
    Chatelanaz, C.
    Henriet, C.
    Jaffry, A.
    Bridey, F.
    Group, T. S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 548 - 549
  • [7] Toward Personalized Treatment for Patients with Low von Willebrand Factor and Quantitative von Willebrand Disease
    O'Donnell, James S.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2021, 47 (02): : 192 - 200
  • [8] Von Willebrand factor and von Willebrand disease - Preface
    Michiels, JJ
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2001, 14 (02) : VII - VII
  • [9] Clinical use of a von Willebrand factor with a low FVIII content to control major bleeding episodes in von Willebrand disease patients: Results from prospective multicentre studies
    Borel-Derlon, A.
    Goudemand, J.
    Rothschild, C.
    Roussel-Robert, V.
    Borg, J.
    Pan-Petesh, B.
    Sie, P.
    Negrier, C.
    Federici, A.
    Henriet, C.
    Chatelanaz, C.
    Bridey, F.
    HAEMOPHILIA, 2012, 18 : 195 - 195
  • [10] Recombinant von willebrand factor kinetics and ultralarge multimer content in severe von willebrand disease patients
    Ragni, M.
    Castaman, G.
    Gill, J. C.
    Kouides, P.
    Chapman, M.
    Sytkowski, A.
    Obermann-Slupetzky, O.
    Presch, I
    Fritsch, S.
    Ewenstein, B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 : 151 - 151
12345